Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Public ClinicalTrials.gov record NCT07214311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.
Study identification
- NCT ID
- NCT07214311
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2026
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2028
- Last update posted
- Aug 18, 2026
2026 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Sarasota | Florida | 34239 | Recruiting |
| Clinical Trial Site | Tamarac | Florida | 33321 | Recruiting |
| Clinical Trial Site | Shreveport | Louisiana | 71103 | Recruiting |
| Clinical Trial Site | Baltimore | Maryland | 21215 | Recruiting |
| Clinical Trial Site | Boston | Massachusetts | 02120 | Recruiting |
| Clinical Trial Site | New York | New York | 10032 | Recruiting |
| Clinical Trial Site | Leland | North Carolina | 28451 | Recruiting |
| Clinical Trial Site | Cincinnati | Ohio | 45267 | Recruiting |
| Clinical Trial Site | Cleveland | Ohio | 44195 | Recruiting |
| Clinical Trial Site | Columbus | Ohio | 43210 | Recruiting |
| Clinical Trial Site | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Clinical Trial Site | Dallas | Texas | 75390 | Recruiting |
| Clinical Trial Site | Edinburg | Texas | 78539 | Recruiting |
| Clinical Trial Site | Salt Lake City | Utah | 84132 | Recruiting |
| Clinical Trial Site | Morgantown | West Virginia | 26506 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07214311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07214311 live on ClinicalTrials.gov.